Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019

Emily Rayens, Mary Kay Rayens, Karen A. Norris

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 1148.

Release date: September 21, 2022; Expiration date: September 21, 2023

Learning Objectives

Upon completion of this activity, participants will be able to:

- Analyze the rate of hospitalizations with fungal infection, based on sex
- Distinguish sociodemographic risk factors for aspergillosis
- Evaluate patterns of fungal infections among hospitalized patients, based on race/ethnicity
- Assess age as a risk factor for fungal infections among inpatients

CME Editor

Amy J. Guinn, BA, MA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Amy J. Guinn, BA, MA, has no relevant financial relationships.

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. Disclosure: Charles P. Vega, MD, has the following relevant financial relationships: served as a consultant or advisor for GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Authors

Emily Rayens, PhD, MPH; Mary Kay Rayens, PhD, MS; and Karen A. Norris, PhD.
Fungal infections cause millions of deaths and tens of millions of infections globally every year (1). Fungal infections are primarily opportunistic, causing moderate to severe disease in immunocompromised patients. Fungal infections also are associated with increased illness rates and substantial healthcare costs, resulting in $6.7 billion in hospitalization costs in the United States in 2018 (2). In addition, fungal infections doubled the average length and cost of hospital stays and risk for death among patients with ≥65 years of age. Our findings suggest that differences in fungal infection diagnostic rates are associated with demographic and socioeconomic factors and highlight an ongoing need for increased physician evaluation of risk for fungal infections.

Fungal pathogens cause millions of deaths and tens of millions of infections globally every year (1). Fungal infections are primarily opportunistic, causing moderate to severe disease in immunocompromised patients. Fungal infections also are associated with increased illness rates and substantial healthcare costs, resulting in $6.7 billion in hospitalization costs in the United States in 2018 (2). In addition, fungal infections doubled the average length and cost of hospital stays and risk for death among patients with ≥65 years of age. Our findings suggest that differences in fungal infection diagnostic rates are associated with demographic and socioeconomic factors and highlight an ongoing need for increased physician evaluation of risk for fungal infections.

**Methods**

**Data Sources**
We used hospital discharge data from the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), from the Agency for Healthcare Research and Quality (20). NIS is the largest database of US hospitalization data, covering >96% of the population (20). HCUP data comprise hospitalizations, rather than unique patients. We use the term patient to refer to inpatient status; we acknowledge that a specific patient might be included ≥1 time in our analyses. For total population per income quartile, we used 2006–2010 American Community Survey (21) results to estimate population percentages, then adjusted these to the 2019 population.

**Element Descriptions**
We used codes from the International Classification of Diseases, 10th Revision (ICD-10), to identify at-risk patients and invasive and noninvasive fungal infections, as previously described (2) (Table). We defined fungal infections and associated risk conditions when relevant ICD-10 codes were recorded as any diagnosis in the hospitalization record. Sex, race, and ethnicity data were provided by patient records in NIS. HCUP excludes the data for sex when the state level patient record identifies the patient as both nonfemale and nonmale. Ethnicity took precedence over race in the HCUP database when both were provided as distinct values in the patient record.

The HCUP dataset predefines each annual income quartile (Q) according to estimated median household income in US dollars of residents living within a patient’s postal code. For 2019, Q1 was $1–$47,999, Q2 was $48,000–$60,999, Q3 was $61,000–$81,999, and Q4 was ≥$82,000. We defined insurance type by the expected primary payer type to which the hospital visit was billed in the HCUP NIS dataset.

We defined age groups as pediatric (0–17 years of age), adult (18–64 years of age), and senior (≥65 years of age). We defined urban-rural status, as previously described (22), and considered counties with >50,000 inhabitants as urban. We calculated rate ratios (RRs) and 95% CIs by using SAS version 9.4 (SAS Institute Inc., https://www.sas.com). We used Prism software (GraphPad Software Inc., https://www.graphpad.com) to create figures.
Table. Number of risk conditions and fungal infections diagnosed among hospitalized patients, United States, 2019*

| Fungal infections and risk conditions | ICD-10 code | No. cases diagnosed |
|--------------------------------------|-------------|---------------------|
| Aspergillosis                         | B44         | 17,825              |
| Invasive                              | B44.0, B44.1, B44.7 | 8,875              |
| Noninvasive                           | B44.2, B44.8 | 4,210               |
| Candidias                             | B37         | 457,080             |
| Invasive                              | B37.1, B37.5, B37.6, B37.7 | 19,920             |
| Noninvasive                           | B37.0, B37.2, B37.3, B37.4, B37.8 | 396,765             |
| Coccidioidomycosis                    | B38         | 8,990               |
| Cryptococcosis                        | B45         | 4,900               |
| Histoplasmosis                        | B39         | 4,880               |
| Mucormycosis                          | B46         | 1,370               |
| Pneumocystosis                        | B59         | 9,725               |
| Other                                 | B35, B36, B40–B43, B47, B48 | 145,925             |
| Unspecified mycoses                   | B49         | 15,540              |

Risk conditions
- Asthma: J45–J46 (2,273,360)
- Autoimmune conditions: G35, G70, K90, L93, M05, M35 (483,850)
- Cancer: C00–C97 (2,869,790)
- Chronic obstructive pulmonary disease: J44 (4,402,564)
- Cirrhosis: K74 (468,950)
- Cystic fibrosis: E84 (29,465)
- Diabetes mellitus: E10–E14 (8,376,979)
- End-stage renal disease: D17 (32,665)
- HIV: B20–B24 (109,180)
- Immunosuppressive disorders: D80–D89 (224,100)
- Influenza: J09–J11 (276,950)
- Myelodysplastic syndrome: D46 (82,170)
- Neutropenia: D70 (194,870)
- Osteomyelitis: M86 (385,450)
- Pneumonia: J12–J18 (2,552,504)
- Sepsis: A40–A41 (2,820,729)
- Transplant history: Z94 (266,580)
- Transplant complications: T86 (145,540)
- Tuberculosis: A16–A19 (3,690)

*Data from ICD-10 codes listed in the Healthcare Cost and Utilization Project, 2019 (20). ICD-10, International Classification of Diseases, 10th Revision.

Results

Nearly 60,000 invasive fungal infections were reported during US hospitalizations in 2019, ≈10% of all diagnosed fungal infections among hospitalized patients. Another 391,000 noninvasive infections, primarily dermophyte, also were diagnosed.

Fungal Infections and Risk Conditions by Sex

Invasive fungal infections were diagnosed more frequently in male patients, at 1.4–3.4 times the rate for female patients (Figure 1, panel A; Appendix Table 1, https://wwnc.cdc.gov/EID/article/28/10/22-0391-App1.pdf). We observed the greatest differences between male and female patients in coccidioidomycosis (RR 2.0, 95% CI 1.9–2.1), pneumocystosis (RR 2.4, 95% CI 2.3–2.5), and cryptococcosis (RR 3.4, 95% CI 3.2–3.7) diagnoses. Noninvasive candidiasis, including vulvovaginal candidiasis, was the only diagnosis made more frequently in female patients, at 1.2 (95% CI 1.2–1.2) times the rate for male patients.

Male patients had ≥1 fungal-associated risk condition diagnosed at 1.2 (95% CI 1.2–1.2) times the rate for female patients (Figure 1, panel B). Of 19 risk conditions we analyzed, 16 were diagnosed more frequently in male patients. We observed the greatest differences in risk conditions between male and female patients for HIV (RR 3.1, 95% CI 3.0–3.1) and osteomyelitis (RR 2.7, 95% CI 2.7–2.7). Asthma (RR 1.7, 95% CI 1.7–1.7), autoimmune diseases (RR 1.9, 95% CI 1.9–1.9), and immunosuppressive disorders (RR 1.1, 95% CI 1.0–1.1) were diagnosed more frequently in female patients.

Fungal Infections and Risk Conditions by Race and Ethnicity

Overall, risk conditions and fungal infections were diagnosed among racial and ethnic subgroups at rates generally consistent with the current racial and ethnic composition of the United States; most (65.9%) cases were diagnosed in non-Hispanic White patients. However, we noted deviations that highlight racial and ethnic health disparities.

Among Black patients, cryptococcosis was diagnosed at 2.5 (95% CI 2.3–2.6) and pneumocystosis at 3.0 (95% CI 2.9–3.2) times the rates for non-Hispanic White patients (Figure 2, panel A). The transplant...
Figure 1. Comparison of rate ratios for fungal infections and risk conditions by sex among hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.

Figure 2. Comparison of rate ratios for fungal infections and risk conditions among non-Hispanic White and Black hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.
Figure 3. Comparison of rate ratios for fungal infections and risk conditions among hospitalized non-Hispanic White and Hispanic patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.

Figure 4. Comparison of rate ratios for fungal infections and risk conditions among hospitalized non-Hispanic White and AA/PI patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. AA/PI, Asian American/Pacific Islander; COPD, chronic obstructive pulmonary disease.
history rate appeared similar, but Black patients were twice as likely as non-Hispanic White patients to have transplant complications during hospitalization, particularly for heart and kidney transplants (Figure 2, panel B; Appendix Table 1). HIV was diagnosed among Black patients at 7.2 (95% CI 7.1–7.3) and tuberculosis at 2.7 (95% CI 2.4–2.9) times the rates for non-Hispanic White patients.

Hispanic patients had fungal infections diagnosed at 0.8 (95% CI 0.8–0.8) times the rate for non-Hispanic White patients; Hispanic patients had decreased rates of aspergillosis, candidiasis, and histoplasmosis (Figure 3, panel A). Rates for coccidioidomycosis (RR 3.4, 95% CI 3.2–3.5), cryptococcosis (RR 2.9, 95% CI 2.7–3.1), and pneumocystosis (RR 1.4, 95% CI 1.3–1.5) were higher among Hispanic than non-Hispanic White patients. HIV was diagnosed among Hispanic patients at 2.4 (95% CI 2.4–2.5) times and tuberculosis at 3.8 (95% CI 3.4–4.1) times the rates for non-Hispanic White patients (Figure 3, panel B). Transplant complications were also moderately elevated in the Hispanic patient cohort.

The overall rate of fungal infection diagnosis in Asian American and Pacific Islander (AA/PI) patients was reduced (RR 0.7, 95% CI 0.7–0.7) compared with non-Hispanic White patients (Figure 4, panel A). Aspergillosis (RR 1.4, 95% CI 1.3–1.5), coccidioidomycosis (RR 2.7, 95% CI 2.5–2.9), and mucormycosis (RR 1.9, 95% CI 1.5–2.5) rates were higher for AA/PI than for non-Hispanic White patients. AA/PI patients had ≥1 fungal-associated risk condition diagnosed at 0.8 (95% CI 0.8–0.8) times the rate for non-Hispanic White patients (Figure 4, panel B). Transplant complications were moderately elevated in the AA/PI cohort, but tuberculosis diagnoses were 9.6 (95% CI 8.7–10.7) times those for non-Hispanic White patients.

Native American patients had coccidioidomycosis diagnosed at 5.9 (95% CI 5.2–6.6) times the rate for non-Hispanic White patients (Figure 5, panel A). Native American patients also had higher rates of cryptococcosis (RR 2.5, 95% CI 1.9–3.3) than non-Hispanic White patients, but the rates of pneumocystosis did not differ between these 2 groups (RR 1.0, 95% CI 0.7–1.3). Rates of invasive aspergillosis and histoplasmosis were moderately reduced among Native American patients. For risk conditions, Native American patients had HIV diagnosed at 1.6 (95% CI 1.5–1.7), osteomyelitis at 1.8 (95% CI 1.8–1.9), and tuberculosis at 3.6 (95% CI 2.6–4.8) times the rates for non-Hispanic White patients (Figure 5, panel B).

**Fungal Infections and Risk Conditions by Payer Type**

Most (86.7%) persons covered by federally funded Medicare are ≥65 years of age (23). In hospitalizations billed to Medicare, fungal infections were diagnosed at 2.0 (95% CI 2.0–2.0) times the rate for hospitalizations billed to private insurance (Figure 7, panel A; Appendix Table 3). The diagnostic rates for aspergillosis (RR 1.4, 95% CI 1.4–1.5), candidiasis (RR 2.0, 95% CI 2.0–2.0), other fungi (RR 2.2, 95% CI 2.2–2.3), and unspecified fungal infections (RR 1.9, 95% CI 1.8–2.0) were particularly elevated among Medicare patients. Only pneumocystosis (RR 0.8, 95% CI 0.8–0.9) rates were notably lower among hospitalizations billed to Medicare than those billed to private insurance. Hospitalizations billed to Medicare had 2.1 (95% CI 2.1–2.1) times the rate of having ≥1 fungal-associated risk condition diagnoses as did hospitalizations billed to private insurance (Figure 7, panel B). Rates for 16 of the 19 risk conditions we investigated were elevated in hospitalizations billed to Medicare, and we noted differences in COPD (RR 4.6, 95% CI 2.6–2.6), cirrhosis (RR 2.5, 95% CI 2.4–2.5), diabetes mellitus (RR 2.5, 95% CI 2.5–2.6), myelodysplastic syndrome (RR 4.8, 95% CI 4.7–4.9), pneumonia (RR 2.7, 95% CI 2.7–2.7), and sep- sis (RR 2.3, 95% CI 2.3–2.3). Conversely, cystic fibrosis was diagnosed at just over one third the frequency (RR 0.4, 95% CI 0.3–0.4) in hospitalizations billed to Medicare compared with those billed to private insurance.
Figure 5. Comparison of rate ratios for fungal infections and risk conditions among hospitalized non-Hispanic White and Native American patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.

Figure 6. Comparison of rate ratios for fungal infections and risk conditions by income among hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Income levels were determined by postal code; patients from postal codes with incomes in the highest quartile were compared with patients from postal codes with incomes in the lowest quartile. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.
Figure 7. Comparison of rate ratios for fungal infections and risk conditions by billing type (private insurance vs. Medicare) among hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.

Figure 8. Comparison of rate ratios for fungal infections and risk conditions by billing type (private insurance vs. Medicaid) among hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.
Factors Associated with Fungal Infection Risk, USA

Figure 9. Comparison of rate ratios for fungal infections and risk conditions by billing type (private insurance vs. self-pay) among hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.

Figure 10. Comparison of rate ratios for fungal infections and risk conditions among adult and senior hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Adult patients are persons 18–64 years of age; senior patients are ≥65 years of age. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.
SYNOPSIS

Federal- and state-funded Medicaid provides free health insurance to persons with low incomes, disabilities, or both (24). Fungal infections were more frequent in hospitalizations billed to Medicaid than those billed to private insurance (Figure 8, panel A). In particular, invasive candidiasis (RR 1.4, 95% CI 1.4–1.5), coccidioidomycosis (RR 1.6, 95% CI 1.5–1.7), cryptococcosis (RR 2.2, 95% CI 2.1–2.4), pneumocystosis (RR 1.3, 95% CI 1.3–1.4), other fungi (RR 1.4, 95% CI 1.4–1.5), and unspecified fungal infections (RR 1.3, 95% CI 1.3–1.4) were diagnosed more frequently, and invasive aspergillosis (RR 0.8, 95% CI 0.8–0.9) and histoplasmosis (RR 0.7, 95% CI 0.7–0.8) were diagnosed less frequently for hospitalizations billed to Medicaid compared with those billed to private insurance. The rates of HIV (RR 3.1, 95% CI 3.1–3.2) and tuberculosis (RR 1.9, 95% CI 1.8–2.1) were higher in hospitalizations billed to Medicaid than those billed to private insurance (Figure 8, panel B). Risk conditions with fewer diagnoses billed to Medicaid than to private insurance included autoimmune diseases (RR 0.6, 95% CI 0.6–0.6), cancer (RR 0.6, 95% CI 0.6–0.6), immunosuppressive disorders (RR 0.7, 95% CI 0.7–0.7), myelodysplastic syndrome (RR 0.4, 95% CI 0.4–0.4), and transplant history (RR 0.5, 95% CI 0.5–0.5).

Hospitalizations billed as self-pay represent patients that are uninsured or underinsured (i.e., <30% estimated insurance coverage). These hospitalizations had a lower frequency of diagnoses for aspergillosis (RR 0.6, 95% CI 0.5–0.6) but elevated frequencies for cryptococcosis (RR 2.2, 95% CI 2.0–2.5) and pneumocystosis (RR 2.2, 95% CI 2.0–2.4) (Figure 9, panel A). Rates of HIV (RR 3.1, 95% CI 3.0–3.2) and tuberculosis (RR 2.4, 95% CI 2.1–2.8) were elevated in hospitalizations billed as self-pay compared with private insurance, but other risk conditions were reduced, including autoimmune diseases (RR 0.5, 95% CI 0.5–0.5), cancer (RR 0.5, 95% CI 0.5–0.5), immunosuppressive disorders (RR 0.5, 95% CI 0.5–0.5), myelodysplastic syndrome (RR 0.4, 95% CI 0.4–0.5), and transplant history (RR 0.3, 95% CI 0.3–0.3) (Figure 9, panel B).

**Fungal Infections and Risk Conditions by Age**

Fungal infection diagnosis rates among senior patients were 1.3 (95% CI 1.3–1.3) times that for adult patients. We noted moderate elevation in the rate of invasive aspergillosis diagnoses among senior patients, but noninvasive candidiasis was diagnosed more frequently (RR 1.4, 95% CI 1.4–1.4) among senior than adult patients (Figure 10, panel A; Appendix Table 4). Fungal infections diagnosed less frequently in senior than adult patients included coccidioidomycosis (RR 0.6, 95% CI 0.6–0.6), cryptococcosis (RR 0.5, 95% CI 0.5–0.5), histoplasmosis (RR 0.8, 95% CI 0.7–0.8), mucormycosis (RR 0.6, 95% CI 0.5–0.6), and pneumocystosis (RR 0.4, 95% CI 0.4–0.4). Senior patients had ≥1 fungal-associated risk condition diagnosed at 1.6 (95% CI 1.6–1.6) times the rate of adult patients (Figure 10, panel B). We also noted elevated rates of COPD (RR 2.4, 95% CI 2.4–2.4), myelodysplastic syndrome (RR 7.2, 95% CI 7.0–7.3), and pneumonia (RR 2.1, 95% CI 2.1–2.1) among senior patients compared with adult patients. Few senior patients had a cystic fibrosis diagnosis, and HIV (RR 0.2, 95% CI 0.2–0.2) diagnoses also were lower than among adult patients.

Despite representing 14.9% of hospitalizations in 2019, pediatric patients accounted for only 4.2% of diagnosed fungal infections and had one third the diagnostic rate (RR 0.3, 95% CI 0.3–0.3) of adult patients (Figure 11, panel A); rates of all fungal pathogens and manifestations were reduced. Pediatric patients had ≥1 fungal-associated risk condition diagnosed at 0.2 (95% CI 0.2–0.2) times the rate for adult patients (Figure 11, panel B). Only the diagnostic rate for cystic fibrosis (RR 1.3, 95% CI 1.2–1.3) was higher among pediatric than adult patients.

**Fungal Infections and Risk Conditions by Rural or Urban Status**

Among patients from urban areas, certain fungal infections were diagnosed more frequently, including coccidioidomycosis at 3.4 (95% CI 3.1–3.8), pneumocystosis at 1.9 (95% CI 1.8–2.0), and aspergillosis at 1.2 (95% CI 1.1–1.2) times the rates for patients from rural areas (Figure 12, panel A; Appendix Table 5). All aspergillosis infections were diagnosed more frequently in urban patients, but noninvasive aspergillosis (RR 1.8, 95% CI 1.6–2.0) had the greatest difference. Infections diagnosed more frequently among rural patients included candidiasis at 1.1 (95% CI 1.1–1.1) and histoplasmosis at 1.6 (95% CI 1.5–1.7) times the rate for urban patients.

Urban patients had much higher rates of HIV (RR 2.9, 95% CI 2.9–2.9) and tuberculosis (RR 2.0, 95% CI 1.8–2.3) than rural patients (Figure 12, panel B). Asthma (RR 1.4, 95% CI 1.4–1.4) and transplants (RR 1.2, 95% CI 1.2–1.2) also were more common among urban patients, consistent with previous reports (25). COPD (RR 1.4, 95% CI 1.4–1.4) and pneumonia (RR 1.3, 95% CI 1.3–1.4) were more frequent among rural patients.

**Discussion**

We analyzed rates of fungal infection diagnoses in hospitalizations on the basis of racial and ethnic
Figure 11. Comparison of rate ratios for fungal infections and risk conditions among adult and pediatric hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Adult patients are persons 18–64 years of age; pediatric patients are ≤17 years of age. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.

Figure 12. Comparison of rate ratios for fungal infections and risk conditions by residential location (urban vs. rural) among hospitalized patients, United States, 2019. A) Diagnosed fungal infections; B) risk conditions. Persons from more urban settings are considered those whose resident county has a population >50,000. Bars and numerals indicated rate ratios; error bars indicate 95% CIs. COPD, chronic obstructive pulmonary disease.
background and socioeconomic status. Our findings demonstrate that health disparities between racial, ethnic, and socioeconomic groups extend to fungal infections, especially for predisposing risk conditions.

In HCUP NIS, male patients had 1.4–3.5 times the rate of invasive fungal infection diagnoses as female patients, a finding supported by existing literature (26). The influence of genetic components by sex has been postulated, as have higher environmental exposure and behavioral risks (26,27). The relationship between sex and susceptibility is more complex than our analyses can capture, but ≥1 risk condition for fungal infection was more frequently diagnosed among male patients.

Aspergillosis was diagnosed more frequently in non-Hispanic White and AA/PI patients than in other racial and ethnic groups. As previously described (3), invasive aspergillosis is closely associated with stem cell and solid organ transplantation, and noninvasive manifestations, including allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis, are more often diagnosed in cystic fibrosis and tuberculosis patients; AA/PI patients have >9 times the rate of tuberculosis diagnoses as non-Hispanic White patients (28). In addition, aspergillosis is the only fungal infection diagnosed more frequently in patients from higher income areas. Higher income is associated with higher probability of receiving a transplant (29,30) and improved patient outcomes in cystic fibrosis care (31), possibly because these patients have better access to healthcare facilities and the financial capacity for regular treatment. Aspergillosis likely is more frequently diagnosed in higher income patients because of their ability to continually seek treatment for associated risk factors. Income differences also could relate to cost of living because aspergillosis is more likely to be diagnosed in urban than rural patients (32).

Candidiasis was diagnosed more frequently in Black patients. Invasive candidiasis was more frequent in male patients, fitting with previous findings (33), but noninvasive candidiasis was more frequent in female patients. Increased rates of candidiasis among senior patients compared with adult patients also is consistent with prior findings (33). All candidiasis clinical manifestations were more frequent in patients from lower income areas. Assessments of the relationship of candidiasis and income are lacking, but these diagnoses might be related to the higher frequency of diabetes in patients from low-income areas (7). This finding also might be an artifact of the relationship between low income and increased frequency of repeat hospitalizations (34). All candidiasis clinical manifestations were diagnosed moderately more frequently in rural patients.

Coccidioidomycosis and histoplasmosis are endemic infections that can affect immunocompetent persons, but severe disease is more common in immunocompromised persons. Coccidioidomycosis is endemic in the US Southwest and histoplasmosis in the Ohio and Mississippi River Valley regions. Our analysis showed coccidioidomycosis was diagnosed more frequently in Hispanic, AA/PI, and Native American adult male patients than in non-Hispanic White or Black, senior, or female patients. Environmental exposure is key in coccidioidomycosis; workers performing soil-disturbing work or exposed to dusty conditions in endemic areas are at increased risk. Black and Hispanic persons are overrepresented in lower wage, more manual labor, and higher risk occupations, including occupations with frequent dust exposure (35,36). Previous reports noted higher frequencies of coccidioidomycosis in AA/PI and Hispanic male adults residing in urban areas, but older state-level data also indicated increased rates in Black compared with non-Hispanic White male persons (36–38).

Non-Hispanic White patients had up to 3 times the rate of histoplasmosis as other racial and ethnic groups. Histoplasmosis diagnoses were higher among adult, low-income, and rural patients. These results are supported by previous reports of histoplasmosis predominantly among middle-aged adult White male persons living in rural areas (39). These demographic variables likely capture persons with environmental or occupational exposure, including persons employed in construction, agriculture, and forestry industries (40).

Historically, cryptococcosis and pneumocystosis were closely tied to HIV, which continues to disproportionately affect Black and Hispanic/Latino populations (41). We found cryptococcosis and pneumocystosis were diagnosed in Black and Hispanic patients at 2–3 times the rate for non-Hispanic White patients. HIV, cryptococcosis, and pneumocystosis frequencies also were elevated in Q1 patients and were far more frequent in adult than senior patients, fitting with previous literature (42). HIV, cryptococcosis, and pneumocystosis rates were elevated in hospitalizations billed to Medicaid or self-pay and in urban patients.

Incidences of mucormycosis, a rare and often fatal infection, has been rising (43). We found mucormycosis diagnoses were more frequent among AA/PI and Hispanic patients than among non-Hispanic White patients. The most common underlying condition for
mucormycosis is diabetes mellitus (43), but diabetes was not diagnosed more frequently in AA/PI or Hispanic populations in our study. We noted no differences in mucormycosis rates by income or insurance type. Adult patients were more likely to have mucormycosis than senior patients, and we noted a slight elevation in diagnoses among urban patients.

Other fungal infections include primarily superficial cutaneous and mucosal infections, which were diagnosed more frequently in senior patients and in hospitalizations billed to Medicare, consistent with previous studies (44). Unspecified mycotic infections also were more frequently diagnosed in senior patients, which could reflect increased mortality and shorter survival times associated with an aging immune response failing to control invasive fungal infections, as previously described (45).

Our results are informative, but our data likely underrepresent the true burden of fungal disease in the United States. Evidence suggests that only half of invasive fungal infections are diagnosed before patient death (46). The sensitivity and specificity of many ICD-10 codes for fungal infections are unknown, and misclassification is possible. HCUP NIS enabled us to comprehensively study fungal infections; however, unique patients cannot be identified in NIS, so our data likely represent multiple hospitalizations per patient. Data collection also could be a limitation because race and ethnicity analyses are limited by single identifiers and failed to represent patients with multiracial or multiethnic identities. In addition, some previously studied racial and ethnic subgroups might not have been included for this variable in the NIS dataset. Finally, hospitals might have reported a private insurance payer type for patients covered by a Medicare-managed care program administered by a private insurance company, potentially underrepresenting differences between payer types.

In conclusion, we provide a comprehensive summary of fungal infections and associated risk conditions among hospitalized patients, including corresponding rate ratios by demographic and socioeconomic factors. These findings are based on bivariate analysis, but future studies could use a multivariable analysis of the potential predictive weight of demographic and socioeconomic risk factors and ≥1 comorbidity to measure evaluated risk for fungal infection by type. Our findings suggest that differences in fungal infection diagnostic rates are associated with demographic and socioeconomic factors. Because fungal infections increase mortality rates and healthcare costs, our results highlight an ongoing need for increased physician evaluation of risk for fungal infections, especially among minority and low-income populations that are disproportionately affected.

Acknowledgments
We thank the participating Healthcare Cost and Utilization Project (HCUP) Data Partners for the state-level data collection efforts involved in creating the National Inpatient Sample (https://www.hcup-us.ahrq.gov/db/htcudatatpartners.jsp).

This work was supported by National Institutes of Health (grant no. 1R01 AI148365-01A1 to K.A.N.), and endowments to K.A.N. from the Georgia Research Alliance and the University of Georgia Research Foundation.

About the Author
Dr. E. Rayens is a postdoctoral research associate at the University of Georgia, Athens, Georgia, USA. Her research interests include fungal disease immunology and epidemiology.

References
1. Bongomin F, Gaço S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi (Basel). 2017;3:57. https://doi.org/10.3390/jof3040057
2. Rayens E, Norris KA. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open Forum Infect Dis. 2022;9:oafb593. https://doi.org/10.1093/ofid/ofab593
3. Rayens E, Norris KA, Cordero JF. Mortality trends in risk conditions and invasive mycotic disease in the United States, 1999–2018. Clin Infect Dis. 2022;74:309–18. https://doi.org/10.1093/cid/ciab536
4. Morris A, Netravali M, Kling HM, Shipley T, Ross T, Sciruba FC, et al. Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:e64–8. https://doi.org/10.1086/591701
5. Pilmis B, Puel A, Lortholary O, Lanternier F. New clinical phenotypes of fungal infections in special hosts. Clin Microbiol Infect. 2016;22:681–7. https://doi.org/10.1016/j.cmi.2016.05.016
6. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137:171–6. https://doi.org/10.1378/chest.09-1103
7. Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. infections in patients with diabetes mellitus. J Clin Med. 2019;8:76. https://doi.org/10.3390/jcm8010076
8. Ghanaat F, Tayek JA. Weight loss and diabetes are new risk factors for the development of invasive aspergillosis infection in non-immunocompromized humans. Clin Pract (Lond). 2017;14:296–301. https://doi.org/10.4172/clinical-practice.1000125
9. Vanderbeke L, Spriet I, Breynaert C, Rijnders BJ, Verweij PE, Wauters J. Invasive pulmonary aspergillosis
41. McCree DH, Williams AM, Chesson HW, Beer L, Jeffries WL IV, Lemons A, et al. Changes in disparities in estimated HIV incidence rates among Black, Hispanic/Latino, and White men who have sex with men (MSM) in the United States, 2010–2015. J Acquir Immune Defic Syndr. 2019;81:57–62. https://doi.org/10.1097/QAI.0000000000001977

42. George IA, Spec A, Powderly WG, Santos CAQ. Comparative epidemiology and outcomes of human immunodeficiency virus (HIV), non-HIV non-transplant, and solid organ transplant associated cryptococcosis: a population-based study. Clin Infect Dis. 2018;66:608–11. https://doi.org/10.1093/cid/cix867

43. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5:26. https://doi.org/10.3390/jof5010026

44. Loo DS. Cutaneous fungal infections in the elderly. Dermatol Clin. 2004;22:33–50. https://doi.org/10.1016/S0733-8635(03)00109-8

45. Barchiesi F, Orsetti E, Mazzanti S, Trave F, Salvi A, Nitti C, et al. Candidemia in the elderly: What does it change? PLoS One. 2017;12:e0176576. https://doi.org/10.1371/journal.pone.0176576

46. Dignani MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000Prime Rep. 2014;6:81. https://doi.org/10.12703/P6-81

Address for correspondence: Emily Rayens, University of Georgia, 119 Carlton St, Athens, GA 30605, USA; email: emily.rayens25@uga.edu
### Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019

**Appendix**

#### Appendix Table 1. Demographic characteristics of hospitalized patients with diagnosed fungal infections, United States, 2019*

| Infections and risk conditions | M    | F    | Non-Hispanic White | Black | Hispanic | Asian American/ | Pacific Islander | Native American | Other | Unknown | Total |
|-------------------------------|------|------|--------------------|-------|---------|----------------|----------------|----------------|-------|---------|-------|
| **Fungal infections**          |      |      |                    |       |         |                |                |                |       |         |       |
| Aspergillosis                 | 9,790 | 7,440 | 11,240 (65.2)      | 2,440 | 14.1   | 1,920 (11.1)  | 740 (4.3)      | 105 (0.6)      | 465   | 2.7     | 340 (2.0) | 17,250 (100) |
| Invasive                      | 62.6  | 37.7  | 50.5               | 46.2  | 45.2  | 69.1           | 43.4           | 38.0           | 30.0  | 4.8     |          |               |
| Noninvasive                   | 32.69 | 18.3  | 25.7               | 22.5  | 24.0  | 33.6           | 16.5           | 19.3           | 14.1  | 2.4     |          |               |
| Noninvasive                   | 2,300 | 1,975 | 2,695 (63.0)       | 705   | 16.5   | 470 (11.0)    | 170 (4.0)      | 25.0 (0.6)     | 125   | 2.9     | 85 (2.0) | 4,275 (100) |
| Candidiasis                   | 14.70 | 10.0  | 12.1               | 13.6  | 11.0   | 15.9           | 10.3           | 10.5           | 7.5   | 12.0    |          |               |
| Coccidioidomycosis            | 176,895 | 271,550 | 300,395 (67.0)    | 74,100 | 16.5  | 38,860 (6.8)  | 9,835 (2.2)    | 3,025 (0.7)    | 11,460 (2.6) | 11,105 (2.5) | 448,480 (100) |
| Invasive                      | 1,130.5 | 1,373.4 | 1,349.5           | 1,404.2 | 908.6 | 917.9         | 1,253.0         | 960.3          | 981.1 | 1,262.2 |          |               |
| Cryptococcosis                | 10,795 | 9,825 | 13,985 (63.6)      | 3,450 | 16.8 | 2,130 (10.3)  | 630 (3.1)       | 130 (0.6)      | 640 (3.1) | 526 (2.5) | 20,590 (100) |
| Noninvasive                   | 68.8  | 49.7  | 58.8               | 65.4  | 50.2  | 58.8           | 53.7           | 53.6           | 53.4  | 58.1    |          |               |
| Noninvasive                   | 150,740 | 236,205 | 258,960 (66.9)    | 64,535 | 16.7 | 33,060 (8.5) | 8,375 (2.2)    | 2,590 (0.7) | 9,940 (2.6) | 9,520 (2.5) | 386,980 (100) |
| Coccioidomycosis              | 5,655 | 3,640 | 4,310 (46.4)       | 1,000 | 10.8  | 2,770 (29.8)  | 555 (6.0)       | 275 (3.0)      | 235 (2.5) | 150 (1.6) | 9,295 (100) |
| Invasive                      | 96.4  | 1,194 | 1,163.4            | 1,222.9 | 779.0 | 781.6         | 1070.5          | 833.2          | 841.0 | 1,092.6 |          |               |
| Cryptococcosis                | 5,545 | 732.6 | 1,300 (26.8)       | 2,025 | 41.8  | 1,175 (24.3)  | 115 (23.0)      | 135 (2.8)      | 55 (1.1) | 235 (4.9) | 105 (2.2) | 4,845 (100) |
| Noninvasive                   | 22.7  | 6.6   | 9.1               | 22.3  | 26.3  | 12.6          | 22.7           | 19.7           | 9.3   | 13.8    |          |               |
| Histoplasmosis                | 2,710 | 2,220 | 3,465 (70.3)       | 750   | 15.2  | 385 (7.8)     | 50 (1.0)        | 15 (0.3)       | 100 (2.0) | 165 (3.3) | 4,930 (100) |
| Mucormycosis                  | 17.3  | 11.2  | 15.6              | 14.2  | 9.1   | 4.7           | 6.2            | 8.4            | 14.6  | 13.7    |          |               |
| Noninvasive                   | 785   | 610   | 755 (44.7)         | 195   | 14.0  | 265 (19.0)    | 70 (5.0)        | 5 (3.8)        | 50 (3.6) | 1,395 (100) |          |               |
| Other                         | 6.0   | 3.1   | 3.4               | 3.7   | 6.2   | 6.5           | 4.6            | 1.3            | 4.4   | 3.9     |          |               |
| Pneumocystis                  | 6,225 | 3,285 | 3,470 (45.9)       | 3,115 | 32.7  | 260 (2.7)    | 45 (0.5)        | 400 (4.2)      | 155 (1.6) | 9,515 (100) |          |               |
| Other                         | 39.8  | 16.6  | 19.6              | 59.0  | 27.6  | 24.3         | 18.6           | 33.5           | 13.7  | 26.8    |          |               |
| Unspecified mycosis           | 84,405 | 57,770 | 93,970 (65.7)    | 21,930 | 15.3 | 16,380 (11.5) | 2,660 (1.9)    | 1,210 (0.8)    | 3,945 (2.6) | 2,850 (2.0) | 142,945 (100) |
| Other                         | 539.5 | 292.2 | 422.2             | 386.0 | 248.3 | 300.1         | 251.8          | 403.6          |        |          |          |               |
| Total hospitalizations‡       | 7,685 | 6,945 | 9,535 (65.2)       | 2,405 | 16.4  | 1,430 (9.8)  | 365 (2.5)       | 90 (0.6)       | 430 (2.9) | 375 (2.6) | 14,630 (100) |
| **Total hospitalizations‡**   | 280,660 | 341,130 | 411,855 (66.3)   | 101,700 | 16.4 | 59,055 (9.5) | 13,630 (2.1) | 4,410 (0.7) | 16,545 (2.7) | 14,645 (2.4) | 621,840 (100) |
| Risk conditions               |      |      |                  |       |       |                |                |                |       |         |       |
| Asthma                        | 730,385 | 321.1 | 1,542,620 (67.9)  | 1,277,495 | 56.2 | 515,305 (22.7) | 285,615 (12.6) | 56,540 (2.5) | 17,785 (0.8) | 70,000 (3.1) | 50,620 (2.2) | 2,273,360 (100) |
| Other                         | 4,669 | 7,801 | 5,739.6           | 9,764.8 | 6,728.8 | 5,276.8       | 5,731.0         | 5,867.6        | 4,472.0 | 6,418.8 |          |               |

* Article DOI: https://doi.org/10.3201/eid2810.220391
| Infections and risk conditions | M | F | Non-Hispanic White | Black | Hispanic | Asian American/ | Pacific Islander | Native American | Other | Unknown | Total |
|-------------------------------|---|---|---------------------|-------|----------|---------------|----------------|----------------|-------|---------|-------|
| Autoimmune conditions        | 143,620 (29.7) | 340,180 (70.3) | 366,810 (75.3) | 57,055 (11.9) | 30,575 (6.3) | 5,945 (1.2) | 2,398 (0.5) | 9,290 (2.1) | 10,550 (2.2) | 3,853,800 (100) |
| Cancer                       | 1,521,980 (53.0) | 1,348,585 (47.0) | 2,004,325 (69.8) | 367,890 (12.8) | 254,915 (9.2) | 92,485 (3.2) | 13,235 (0.5) | 78,775 (2.7) | 60,165 (2.1) | 2,889,790 (100) |
| COPD                         | 2,096,330 (47.6) | 2,306,059 (52.4) | 3,382,299 (76.8) | 564,275 (12.8) | 214,160 (4.9) | 50,165 (1.1) | 25,505 (0.6) | 78,270 (1.8) | 88,390 (2.0) | 4,402,564 (100) |
| Cirrhosis                    | 13,398.2 | 11,669.0 | 15,192.95 | 10,692.7 | 5,046.1 | 4,881.9 | 10,335.2 | 6,560.8 | 7,808.7 | 12,428.9 |
| Cystic fibrosis              | 1,549.6 | 1,146.0 | 1,382.89 | 946.4 | 1,690.8 | 1,138.2 | 2,122.4 | 1,060.4 | 752.2 | 1,324.1 |
| Diabetes mellitus            | 4,288,140 (51.2) | 3,754,220 (48.8) | 5,176,179 (61.8) | 1,495,965 (17.9) | 993,595 (11.8) | 237,865 (2.8) | 70,310 (0.8) | 229,395 (2.7) | 173,350 (2.1) | 8,376,979 (100) |
| End-stage renal disease      | 16,085 (49.2) | 16,560 (50.8) | 20,690 (63.3) | 5,390 (16.5) | 3,855 (11.8) | 865 (2.6) | 185 (0.6) | 980 (3.0) | 700 (2.1) | 32,665 |
| HIV                          | 77,360 (70.9) | 31,780 (29.1) | 32,470 (28.9) | 61,230,557 (47.0) | 14,955 (13.7) | 1,038 (0.9) | 565 (0.5) | 3,550 (3.3) | 1,140 (1.0) | 109,180 (100) |
| Immunosuppressive disorders  | 96,465 (41.3) | 127,615 (56.9) | 139,775 (62.4) | 51,975 (23.2) | 17,075 (7.7) | 3,825 (1.7) | 1,045 (0.5) | 5,245 (2.2) | 4,980 (2.2) | 224,100 (100) |
| Influenza                    | 127,555 (46.1) | 149,385 (53.9) | 170,445 (61.2) | 45,675 (16.5) | 34,610 (12.5) | 7,915 (2.9) | 2,460 (0.9) | 8,475 (3.2) | 6,970 (2.5) | 276,950 (100) |
| Myelodysplastic syndrome     | 45,735 (55.7) | 36,435 (44.3) | 64,630 (77.4) | 7,015 (6.5) | 5,505 (6.7) | 2,455 (3.0) | 310 (0.4) | 1,121 (2.1) | 1,520 (1.8) | 82,170 (100) |
| Neutropenia                  | 94,960 (48.8) | 99,645 (51.2) | 123,965 (63.6) | 27,140 (13.9) | 24,295 (12.5) | 7,345 (3.8) | 1,015 (0.5) | 6,495 (3.3) | 4,815 (2.4) | 194,870 (100) |
| Osteomyelitis                | 607.2 | 560.5 | 556.80 | 514.29 | 772.45 | 685.51 | 419.53 | 544.43 | 407.71 | 550.11 |
| Pneumonia                    | 1,673.8 | 625.1 | 1,080.52 | 1,312.44 | 1,111.32 | 501.65 | 1,986.10 | 808.05 | 646.68 | 1,086.18 |
| Sepsis                       | 1,279,085 (50.1) | 1,273,713 (49.9) | 1,771,624 (69.4) | 344,900 (13.5) | 228,025 (0.9) | 63,876 (2.5) | 19,045 (0.8) | 66,150 (2.2) | 58,790 (2.3) | 2,552,504 (100) |
| Tuberculosis                 | 8,178.8 | 6,439.4 | 7,958.2 | 6,528.1 | 5,384.6 | 5,961.0 | 7,871.8 | 5,544.9 | 5,139.7 | 7,206.2 |
| Transplant history           | 1,644,205 (51.1) | 1,347,396 (48.9) | 1,879,444 (66.6) | 388,845 (13.8) | 308,215 (10.9) | 85,670 (3.0) | 23,125 (0.8) | 78,960 (2.7) | 58,070 (2.1) | 2,820,729 (100) |
| Transplant complications     | 526.1 | 319.8 | 335.28 | 667.7 | 505.53 | 563.2 | 473.3 | 327.3 | 278.3 | 411.0 |
| Total hospitalizations       | 8,791,520 (48.8) | 9,125,959 (51.2) | 11,870,000 (65.9) | 2,923,465 (16.2) | 1,791,595 (10.0) | 442,925 (2.5) | 125,595 (0.7) | 467,400 (2.6) | 387,695 (2.2) | 18,088,000 (100) |

*Data collected from the Healthcare Cost and Utilization Project (HCUP), 2019 (https://www.hcup-us.ahrq.gov/researchview.jsp). Estimates suppressed in keeping with HCUP protocol. Values represent % of population. COPD, chronic obstructive pulmonary disease.

†Estimates suppressed in keeping with HCUP protocol.

‡Totals are summed by pathway without duplication of values included in invasive/non-invasive types.
### Appendix Table 2. Median household income by ZIP code of hospitalized patients with diagnosed fungal infections, United States, 2019*

| Population, infections, and risk conditions | Q1, <$47,999 | Q2, $48,000–$60,999 | Q3, $61,000–$81,999 | Q4, >$82,000 | Q4/Q1 population rate (95% CI) |
|--------------------------------------------|--------------|----------------------|----------------------|--------------|-----------------------------|
| Estimated population                       | 816,886,938  | 766,639,454          | 816,266,811          | 872,206,797  | NA                          |
| Total inpatient visits                     | 10,584,320   | 8,811,375            | 8,494,420            | 6,935,525    | 0.61 (0.61–0.61)            |
| **Fungal infections**                      |              |                      |                      |              |                             |
| Aspergillosis                              |              |                      |                      |              |                             |
| Invasive                                   |              |                      |                      |              |                             |
| Noninvasive                                |              |                      |                      |              |                             |
| Candidiasis                                |              |                      |                      |              |                             |
| Invasive                                   |              |                      |                      |              |                             |
| Noninvasive                                |              |                      |                      |              |                             |
| Coccidioidomyces                           |              |                      |                      |              |                             |
| Cryptococcos                               |              |                      |                      |              |                             |
| Histoplasmosis                             |              |                      |                      |              |                             |
| Mucomycosis                                |              |                      |                      |              |                             |
| Pneumocystis                               |              |                      |                      |              |                             |
| Other                                      |              |                      |                      |              |                             |
| Unspecified mycoses                        |              |                      |                      |              |                             |
| **Total hospitalizations†**                |              |                      |                      |              |                             |
| **Risk conditions**                        |              |                      |                      |              |                             |
| Asthma                                     |              |                      |                      |              |                             |
| Autoimmune conditions                      |              |                      |                      |              |                             |
| Cancer                                     |              |                      |                      |              |                             |
| COPD                                       |              |                      |                      |              |                             |
| Cirrhosis                                  |              |                      |                      |              |                             |
| Cystic fibrosis                            |              |                      |                      |              |                             |
| Diabetes mellitus                          |              |                      |                      |              |                             |

*Income quartiles are unweighted. *1 Includes hospitalized patients aged 0–17 years.
## Population, Infections, and Risk Conditions

| Condition                                | Q1, <$47,999 | Q2, $48,000–$60,999 | Q3, $61,000–$81,999 | Q4, >$82,000 | Q4/Q1 population rate (95% CI) |
|------------------------------------------|--------------|-----------------------|----------------------|--------------|--------------------------------|
| End-stage renal disease                  | 9,330 (28.6) | 7,915 (24.2)          | 7,645 (23.4)         | 7,220 (22.1) | 1.18 (1.15–1.22)               |
| HIV                                      | 51,375 (47.06) | 23,385 (21.45)       | 17,875 (16.37)       | 11,915 (10.91) | 0.35 (0.35–0.36)               |
| Immunosuppressive disorders              | 62,860 (28.05) | 52,260 (23.32)       | 55,725 (24.87)       | 49,835 (22.24) | 1.21 (1.20–1.22)               |
| Influenza                                | 593.98       | 593.10                | 856.02               | 718.55       | 1.21 (1.20–1.22)               |
| Myelodysplastic syndrome                 | 88,280 (31.88) | 70,375 (25.41)       | 64,935 (23.45)       | 48,700 (17.58) | 0.84 (0.83–0.85)               |
| Neutropenia                              | 476.70       | 519.78                | 577.26               | 663.18       | 1.31 (1.30–1.41)               |
| Osteomyelitis                            | 134,405 (34.87) | 97,805 (25.37)       | 85,910 (22.92)       | 58,515 (15.18) | 0.66 (0.66–0.67)               |
| Pneumonia                                | 844,460 (33.08) | 663,554 (26.00)     | 571,840 (22.40)      | 427,200 (16.74) | 0.77 (0.77–0.78)               |
| Sepsis                                   | 871,895 (30.91) | 700,770 (24.84)      | 666,555 (23.63)      | 526,720 (18.67) | 0.92 (0.92–0.93)               |
| Transplant history                       | 8,237.61     | 7,952.02              | 7,846.97             | 7,594.52     | 1.16 (1.15–1.17)               |
| Transplant complications                 | 68,115 (25.55) | 64,850 (24.33)       | 68,865 (25.83)       | 60,675 (22.76) | 1.36 (135–1.37)               |
| Tuberculosis                             | 1,155 (31.30) | 800 (21.68)           | 935 (25.34)           | 690 (18.70)  | 0.91 (0.83–1.00)               |
| Total hospitalizations                    | 5,710,745 (31.71) | 4,554,483 (25.29)   | 4,202,835 (23.34)    | 3,226,517 (17.92) | 0.86 (0.86–0.86)               |

*Data collected from the Healthcare Cost and Utilization Project, 2019 ([https://www.hcup-us.ahrq.gov/nisoverview.jsp](https://www.hcup-us.ahrq.gov/nisoverview.jsp)). Values represent no. (%), population rate/100,000 persons. COPD, chronic obstructive pulmonary disease; NA, not applicable; Q, quartile.

†Totals are summed by pathogen without duplication of values included in invasive or noninvasive types.

Highlighting indicates the following rate ratios:

- <0.49
- 0.50–0.75
- 1.25–1.49
- 1.50–1.99
- 2.00–2.99
| Infections and risk conditions | Medicare | Medicaid | Private | Self-Pay | Other | Unknown | Total |
|-------------------------------|---------|---------|---------|---------|-------|---------|-------|
| **Fungal infections**         |         |         |         |         |       |         |       |
| Aspergillosis                 | 8,880   | 3,105   | 4,425   | 375     | 445   | 17,250  | 48.71 |
| Invasive                      | 61.12   | 39.17   | 43.19   | 24.57   | 38.93 |         |       |
| Noninvasive                   | 4,620   | 1,425   | 2,280   | 185     | 205   | 8,725   |       |
| Invasive                      | 31.82   | 22.24   | 17.93   | 12.12   |       | 24.63   |       |
| Noninvasive                   | 1,975   | 930     | 1,140   | 100     | 125   | 4,275   |       |
| Candidiasis                   | 13.59   | 11.73   | 11.12   | 6.55    | 10.94 | 33.08   |       |
| Cryptococcosis                | 201,400 | 71,345  | 47,495  | 12,640  | 9,665 | 386,980 |       |
| Histoplasmosis                | 1,503   | 900     | 727     | 828     | 845   | 1,092   |       |
| Mucormycosis                  | 3,635   | 2,740   | 2,220   | 345     | 345   | 9,295   |       |
| Pneumocystosis                | 25.01   | 34.56   | 21.65   | 22.61   | 30.18 | 26.24   |       |
| Other                         | 1,475   | 1,680   | 975     | 325     | 105   | 4,845   |       |
| Unspecified mycoses           | 12.01   | 21.19   | 9.51    | 21.30   | 9.19  | 13.68   |       |
| Total hospitalizations†       | 3,344   | 1,179   | 120.8   | 21,400  | 16,225| 621,840 |       |
| **Risk conditions**           |         |         |         |         |       |         |       |
| Asthma                        | 831,755 | 637,055 | 651,185 | 86,845  | 63,910| 2,273,360|       |
| Autoimmune conditions         | 5,732   | 8,036   | 6,353   | 5,961   | 5,590 | 12,741  |       |
| Cancer                        | 303,753 | 51,330  | 109,345 | 8,530   | 10,365| 483,850 |       |
| COPD                          | 2,090   | 647.52  | 1,066   | 588.9   | 906.7 | 1,167   |       |
| Cirrhosis                     | 1,468   | 322,505 | 755,055 | 60,895  | 81,560| 2,869,790|       |
| Cystic fibrosis               | 3,176   | 528,225 | 488,745 | 89,090  | 115,770| 4,402,564|       |
| Diabetes mellitus             | 21,866  | 6,635   | 4,768   | 5,838   | 10,127| 9,915   |       |
| End-stage renal disease       | 275,610 | 83,775  | 79,050  | 16,230  | 13,795| 468,950 |       |
| HIE                           | 1,897   | 1,056   | 771     | 1,063   | 1,206 | 1,324   |       |
| HIV                           | 5,845   | 9,990   | 11,780  | 675     | 1,170 | 29,465  |       |
| Other                         | 40.24   | 126.02  | 114.91  | 36.57   | 102.35| 83.19   |       |
| Total hospitalizations†       | 344,640 | 117,915 | 120,970 | 21,400  | 16,225| 621,840 |       |
| Infections and risk conditions                      | Payer type | Medicare | Medicaid | Private | Self-Pay | Other | Unknown | Total   |
|----------------------------------------------------|------------|----------|----------|---------|----------|-------|---------|---------|
| **Immunosuppressive disorders**                    |            | 255.93   | 538.34   | 172.28  | 535.07   | 290.44| 419.27  | 308.29  |
| **Influenza**                                      |            | 791.87   | 419.45   | 635.96  | 323.40   | 482.02| 521.24  | 632.86  |
| **Myelodysplastic syndrome**                       |            | 142,720  | 56,915   | 58,930  | 11,20    | 6,820 | 305.01  | 276,950 |
| **Neutropenia**                                    |            | 982.06   | 717.98   | 574.99  | 737.89   | 596.62| 691.22  | 781.86  |
| **Osteomyelitis**                                  |            | 461.93   | 38.10    | 96.29   | 40.30    | 132.97| 141.72  | 232.01  |
| **Pneumonia**                                      |            | 79,860   | 37,430   | 66,255  | 5,020    | 6,085 | 220.12  | 194,870 |
| **Sepsis**                                         |            | 204,360  | 77,240   | 73,795  | 17,445   | 5,020 | 498.58  | 224,100 |
| **Transplant history**                             |            | 1,406.05 | 974.38   | 719.68  | 1,143.21 | 1,064.65| 997.18  | 1,087.97|
| **Pneumonia**                                      |            | 1,613,434| 370,160  | 421,675 | 78,825   | 65,615| 279.50  | 2,552,502|
| **Sepsis**                                         |            | 1,666,405| 429,545  | 513,320 | 112,385  | 76,250| 2,715   | 2,820,730|
| **Transplant history**                             |            | 1,119.82 | 540.67   | 666.02  | 189.39   | 480.71| 441.93  | 752.60  |
| **Transplant complications**                       |            | 601.21   | 106.76   | 363.95  | 115.34   | 235.76| 410.96  | 1,455,400|
| **Tuberculosis**                                    |            | 1,300    | 1,165    | 780.21  | 280.76   | 160.43| 3,690   | 4,410.96|
| **Total hospitalizations**                         |            | 10,670,000| 2,697,710| 3,542,045| 584,425 | 494,330| 18,088,100| 18,088,100|

*Data collected from the Healthcare Cost and Utilization Project (HCUP), 2019 (https://www.hcup-us.ahrq.gov/nisoverview.jsp). Values represent no. (%), population rate/100,000 persons. COPD, chronic obstructive pulmonary disease.

†Estimates suppressed in keeping with HCUP protocol.

‡Totals are summed by pathogen without duplication of values included in invasive/non-invasive types.
## Appendix Table 4. Age groups of hospitalized patients with diagnosed fungal infections, United States, 2019*

| Infections and risk conditions | Pediatric, 0–17 y | Age group, y | Senior, ≥65 y | Total |
|-------------------------------|------------------|--------------|---------------|-------|
| **Fungal Infections**         |                  |              |               |       |
| Aspergillosis                 | 835 (4.8)        | 8,960 (51.9) | 7,455 (43.2)  | 17,250 (100) |
| Invasive                      | 16.06            | 53.34        | 55.55         | 48.70  |
| Noninvasive                   | 280 (3.2)        | 4,560 (52.3) | 3,885 (44.5)  | 8,725 (100) |
| Candidiasis                   | 5.39             | 27.15        | 28.95         | 24.63  |
| Noninvasive                   | 350 (8.2)        | 2,335 (54.6) | 1,590 (37.2)  | 4,275 (100) |
| Invasive                      | 6.73             | 13.90        | 13.90         | 12.07  |
| Candidiasis                   | 21,290 (4.7)     | 204,470 (45.7) | 222,414 (49.6) | 448,480 (100) |
| Noninvasive                   | 409.47           | 1,219.08     | 1,657.20      | 1266.21 |
| Invasive                      | 16.35            | 61.26        | 70.41         | 58.13  |
| Noninvasive                   | 18,770 (4.9)     | 173,825 (44.9) | 194,380 (50.2) | 386,980 (100) |
| Risk conditions               |                  |              |               |       |
| **Asthma**                    | 361.00           | 1,034.85     | 1,448.31      | 1,912.38 |
| **Autoimmune conditions**     | 175 (1.9)        | 6,195 (66.6) | 2,925 (31.5)  | 9,295 (100) |
| **Cancer**                    | 4.37             | 3.66         | 2.19          | 2.64   |
| **Cryptococcosis**            | 36 (1.2)         | 3,465 (71.5) | 1,320 (27.2)  | 4,845 (100) |
| **Histoplasmosis**            | 1.15             | 20.63        | 9.84          | 13.85  |
| **Mucormycosis**              | 200 (4.1)        | 2,965 (60.1) | 1,765 (35.8)  | 4,930 (100) |
| **Pneumocystis**              | 4,04             | 42.45        | 16.21         | 26.86  |
| **Other**                     | 3,805 (2.7)      | 68,435 (48.2) | 69,675 (49.1) | 141,915 (100) |
| **Unspecified mycoses**       | 73.18            | 407.42       | 519.14        | 400.67 |
| **Total hospitalizations†**   | 26,470 (4.3)     | 291,510 (46.9) | 303,855 (48.9) | 621,840 (100) |
| **Total hospitalizations†**   | 509.09           | 1,735.48     | 2,264.00      | 1,755.67 |

*Data are expressed in hospitalization rate per 100,000 population and as a percentage of total hospitalizations.

†Includes unspecified mycoses.
### Infections and risk conditions

| Infections and risk conditions | Pediatric, 0–17 y | Adult, 18–64 y | Senior, >65 y | Total |
|-------------------------------|------------------|----------------|--------------|-------|
| Total hospitalizations        | 517,940 (2.9%)   | 7,698,275 (42.7%) | 9,792,240 (54.4%) | 18,008,695 (100%) |

*Data collected from the Healthcare Cost and Utilization Project, 2019 (https://www.hcup-us.ahrq.gov/nisoverview.jsp). Values represent no. (%) population rate/100,000 persons. COPD, chronic obstructive pulmonary disease.

†Totals are summed by pathogen without duplication of values included in invasive or noninvasive types.
### Appendix Table 5. Urban or rural status of hospitalized patients with diagnosed fungal infections, United States, 2019*

| Infections and risk conditions | Central metro counties, >1 million | Fringe metro counties, >1 million | Urban, 250,000–999,999 | Urban, 500,000–249,999 | Rural, 10,000–49,999 | Rural, <10,000 | Urban/rural population rate (95% CI) |
|--------------------------------|-----------------------------------|-----------------------------------|------------------------|------------------------|-----------------|-----------------|-------------------------------------|
| **Fungal infections**          |                                   |                                   |                        |                        |                 |                 |                                     |
| Aspergillosis                  | 5,860 (33.97)                     | 4,030 (23.36)                     | 3,435 (19.91)          | 1,455 (8.43)           | 1,280 (7.42)    | 1,050 (6.09)    | 1.19 (1.14–1.24)                  |
| Invasive                       | 56.17                             | 47.15                             | 46.38                  | 44.56                  | 39.89           | 44.57           |                                     |
| Noninvasive                    | 2,920 (33.47)                     | 2,070 (23.72)                     | 1,790 (20.52)          | 720 (8.25)             | 615 (7.05)      | 530 (6.07)      | 1.23 (1.16–1.31)                  |
| Candidiasis                    | 1,525 (35.67)                     | 1,025 (29.38)                     | 875 (20.47)            | 420 (8.82)             | 130 (3.04)      | 170 (3.98)      | 1.80 (1.63–2.00)                  |
| Invasive                       | 14.62                             | 11.99                             | 11.81                  | 12.86                  | 4.05            | 7.22            |                                     |
| Noninvasive                    | 122,470 (27.31)                   | 105,925 (23.62)                   | 97,300 (21.70)         | 42,550 (9.49)          | 44,770 (9.98)   | 32,915 (7.34)   | 0.89 (0.88–0.90)                  |
| Candidiasis                    | 58.81                             | 52.60                             | 57.78                  | 54.81                  | 69.81           | 64.74           |                                     |
| Noninvasive                    | 104,920 (27.11)                   | 91,425 (23.63)                    | 84,110 (21.73)         | 37,105 (9.59)          | 38,990 (10.08)  | 28,265 (7.30)   | 0.89 (0.88–0.89)                  |
| **Coccidioidomycosis**         | 3,910 (42.07)                     | 915 (9.84)                        | 3,275 (35.23)          | 575 (6.19)             | 300 (3.23)      | 175 (1.88)      | 3.43 (3.13–3.76)                  |
| Cryptococcosis                 | 1,675 (34.57)                     | 880 (18.16)                       | 915 (18.89)            | 455 (9.39)             | 365 (7.53)      | 395 (8.15)      | 0.97 (0.89–1.05)                  |
| Histoplasmosis                 | 1,275 (25.86)                     | 1,015 (20.59)                     | 910 (18.46)            | 545 (11.05)            | 625 (12.68)     | 520 (10.55)     | 0.61 (0.58–0.66)                  |
| Mucormycosis                   | 465 (33.33)                       | 375 (26.88)                       | 270 (19.35)            | 90 (6.45)              | 115 (8.24)      | 70 (5.02)       | 1.22 (1.05–1.43)                  |
| Pneumocystosis                 | 469.61                            | 398.24                            | 385.46                | 337.15                 | 338.41          | 318.58          | 1.27 (1.25–1.28)                  |
| Other                          | 4,450 (30.42)                     | 3,660 (25.02)                     | 2,785 (19.04)          | 1,315 (8.99)           | 1,260 (8.61)    | 1,040 (7.11)    | 1.00 (0.95–1.04)                  |
| Unspecified mycoses            | 42.66                             | 42.83                             | 37.60                 | 40.27                  | 39.26           | 44.15           |                                     |
| **Total hospitalizations**     | 182,075 (29.28)                   | 147,225 (23.68)                   | 131,400 (21.13)        | 56,085 (9.02)          | 57,800 (9.29)   | 42,390 (6.82)   | 0.97 (0.96–0.98)                  |
| Risk conditions                | 1,745.35                          | 1,722.65                          | 1,774.04              | 1,717.47               | 1,801.12        | 1,799.43        |                                     |
| **Asthma**                     | 772,790 (33.99)                   | 564,525 (24.8)                    | 463,620 (20.39)        | 190,685 (8.39)         | 163,355 (7.19)  | 105,625 (4.63)  | 1.39 (1.38–1.40)                  |
| Autoimmune conditions          | 126,655 (26.18)                   | 130,320 (26.93)                   | 103,655 (21.42)        | 48,130 (9.53)          | 43,665 (9.02)   | 30,120 (6.83)   | 1.04 (1.03–1.05)                  |
| **Cancer**                     | 1,213.56                          | 1,524.85                          | 1,399.46              | 1,473.86               | 1,360.65        | 1,278.57        |                                     |
| **COPD**                       | 838,145 (29.21)                   | 735,175 (25.62)                   | 578,815 (20.17)        | 257,855 (8.99)         | 254,220 (8.68)  | 194,620 (6.78)  | 1.01 (1.01–1.01)                  |
| **Cirrhosis**                  | 8,034.35                          | 8,602.16                          | 7,814.64              | 7,890.18               | 7,921.78        | 8,261.52        |                                     |
| **Cystic fibrosis**            | 2,568.91                          | 2,233.56                          | 2,542.71              | 2,871.94               | 2,957.52        | 3,108.52        |                                     |
| **Diabetes mellitus**          | 2,568.91                          | 2,233.56                          | 2,542.71              | 2,871.94               | 2,957.52        | 3,108.52        |                                     |
| **End-stage renal disease**    | 11,000 (33.68)                    | 8,235 (25.21)                     | 6,345 (19.42)          | 2,680 (8.20)           | 2,325 (7.11)    | 1,900 (5.82)    | 1.26 (1.22–1.30)                  |
| Infections and risk conditions | Central metro counties, >1 million | Fringe metro counties, >1 million | Urban, 250,000–999,999 | Urban, 50,000–249,999 | Rural, 10,000–49,999 | Rural, <10,000 | Urban/rural population rate (95% CI) |
|-------------------------------|-----------------------------------|-----------------------------------|------------------------|------------------------|----------------------|------------------|-----------------------------------|
| HIV                           | 57,095 (52.29)                   | 18,600 (17.04)                   | 18,435 (16.88)        | 5,735 (5.25)           | 3,925 (3.59)         | 2,925 (2.62)     | 2.93 (2.86–3.01)                  |
| Immunosuppressive disorders   | 67,480 (30.11)                   | 59,315 (26.47)                   | 46,070 (20.56)        | 19,920 (8.89)          | 17,450 (7.79)        | 13,105 (5.85)    | 1.18 (1.17–1.20)                  |
| Influenza                     | 80,280 (28.99)                   | 64,670 (23.35)                   | 59,000 (21.30)        | 25,705 (9.28)          | 26,305 (9.50)        | 19,665 (7.1)     | 0.94 (0.93–0.95)                  |
| Myelodysplastic syndrome      | 22,395 (27.31)                   | 23,295 (28.31)                   | 16,695 (20.36)        | 7,580 (9.24)           | 6,860 (8.37)         | 5,180 (6.37)     | 1.09 (1.07–1.11)                  |
| Neutropenia                   | 59,330 (30.66)                   | 50,240 (25.96)                   | 39,895 (20.62)        | 16,665 (8.61)          | 15,600 (8.06)        | 11,765 (6.08)    | 1.14 (1.13–1.15)                  |
| Osteomyelitis                 | 117,340 (30.73)                  | 88,070 (23.07)                   | 80,165 (21.00)        | 33,715 (8.83)          | 36,005 (9.43)        | 26,530 (6.95)    | 0.96 (0.95–0.97)                  |
| Pneumonia                     | 666,010 (26.09)                  | 581,085 (22.77)                  | 524,365 (20.54)       | 257,570 (10.09)        | 282,570 (11.07)      | 228,369 (8.95)   | 0.75 (0.74–0.75)                  |
| Sepsis                        | 839,780 (29.77)                  | 653,275 (23.16)                  | 601,720 (21.33)       | 263,450 (9.34)         | 260,880 (9.25)       | 183,180 (6.49)   | 1.00 (0.99–1.00)                  |
| Transplant history            | 83,315 (31.25)                   | 70,600 (26.48)                   | 52,855 (19.83)        | 22,650 (8.50)          | 21,780 (8.17)        | 14,405 (5.40)    | 1.19 (1.18–1.20)                  |
| Transplant complications      | 51,475 (35.37)                   | 38,115 (26.19)                   | 27,275 (18.74)        | 10,575 (7.27)          | 10,355 (7.11)        | 7,215 (4.96)     | 1.36 (1.34–1.38)                  |
| Tuberculosis                  | 493.46 (445.98)                  | 368.24 (382.44)                  | 323.83 (302.83)       | 322.67 (306.27)        | 306 (306.27)         | 306 (306.27)     | 1.95 (1.82–2.30)                  |
| Total hospitalizations        | 5,163,780 (28.67)                | 4,283,634 (23.79)                | 3,750,883 (20.83)     | 1,706,020 (9.47)       | 1,718,793 (9.54)     | 1,292,533 (7.18) | 0.93 (0.93–0.93)                  |

*Data collected from the Healthcare Cost and Utilization Project, 2019 (https://www.hcup-us.ahrq.gov/nisoverview.jsp). Values represent no. (%), population rate/100,000 persons. COPD, chronic obstructive pulmonary disease.

Highlighting indicates the following rate ratios: <0.75 1.25–1.49 1.50–1.99 2.00–2.99 >3.00